Current Diabetes Reports

, Volume 7, Issue 3, pp 208–217 | Cite as

Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update

  • Sudha Ganne
  • Surender K. Arora
  • Olena Dotsenko
  • Samy I. McFarlane
  • Adam Whaley-Connell
Article

Abstract

Hypertension (HTN) and type 2 diabetes mellitus (T2DM) are emerging as epidemics of the 21st century and are important components of the metabolic syndrome (MS). Evidence demonstrates a relationship between HTN, T2DM, and several vascular and metabolic abnormalities that are components of the MS. HTN affects nearly 70 million Americans and over one billion worldwide; likewise, the MS affects 44% of the US population above the age of 60 years and is rapidly increasing. HTN associated with the MS has certain pathophysiologic characteristics that provide clinical challenges. There is growing evidence that tissue activation of the renin-angiotensin system contributes to endothelial dysfunction, microalbuminuria, insulin resistance, and subsequent increased risk for cardiovascular and chronic kidney disease. The notion that HTN is a metabolic as well as a vascular disease provides a new treatment paradigm.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lorenzo C, Okoloise M, Williams K, et al.: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003, 26:3153–3159.PubMedCrossRefGoogle Scholar
  2. 2.
    Palaniappan L, Carnethon MR, Wang Y, et al.: Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:788–793.PubMedCrossRefGoogle Scholar
  3. 3.
    Eckel RH, Grundy SM, Zimmet PA: The metabolic syndrome. Lancet 2005, 365:1415–1428.PubMedCrossRefGoogle Scholar
  4. 4.
    Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  5. 5.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  6. 6.
    Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136–141.PubMedCrossRefGoogle Scholar
  7. 7.
    Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.PubMedCrossRefGoogle Scholar
  8. 8.
    Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, JAMA 2003, 289:2560–2571.PubMedCrossRefGoogle Scholar
  9. 9.
    McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.PubMedCrossRefGoogle Scholar
  10. 10.
    Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374–381.PubMedCrossRefGoogle Scholar
  11. 11.
    Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.PubMedGoogle Scholar
  12. 12.
    Grunfeld B, Balzareti M, Romo M, et al.: Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994, 23(suppl 1):I12–I15.PubMedGoogle Scholar
  13. 13.
    Steinberg HO, Chaker H, Leaming R, et al.: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601–2610.PubMedCrossRefGoogle Scholar
  14. 14.
    El-Atat F, Aneja A, McFarlane S, Sowers J: Obesity and hypertension. Endocrinol Metab Clin North Am 2003, 32:823–854.PubMedCrossRefGoogle Scholar
  15. 15.
    Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597–H1602.PubMedCrossRefGoogle Scholar
  16. 16.
    Castro JP, El-Atat FA, McFarlane SI, et al.: Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003, 5:393–401.PubMedCrossRefGoogle Scholar
  17. 17.
    Tuck ML, Sowers J, Dornfield L, et al.: The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N Engl J Med 1981, 304:930–933.PubMedCrossRefGoogle Scholar
  18. 18.
    Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127–137.PubMedCrossRefGoogle Scholar
  19. 19.
    Weyer C, Pratley RE, Snitker Spraul M, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531–537.PubMedGoogle Scholar
  20. 20.
    Landsberg L, Young JB: Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int J Obes 1985, 9(suppl 2):63–68.PubMedGoogle Scholar
  21. 21.
    Zhang R, Reisin E: Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000, 13:1308–1314.PubMedCrossRefGoogle Scholar
  22. 22.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  23. 23.
    Yusuf S, Sleight P, Pogue Bosch J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  24. 24.
    Lindholm LH, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879–1886.PubMedCrossRefGoogle Scholar
  25. 25.
    Henriksen EJ, Jacob S, Kinnick TR, et al.: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884–890.PubMedGoogle Scholar
  26. 26.
    El-Atat F, McFarlane SI, Sowers JR: Diabetes, hypertension and cardiovascular derangements: update on the pathophysiology and management. Curr Hypertens Rep 2004, 6:215–223.PubMedCrossRefGoogle Scholar
  27. 27.
    McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H–37H.PubMedCrossRefGoogle Scholar
  28. 28.
    Schupp M, Janke J, Clasen R, et al.: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054–2057.PubMedCrossRefGoogle Scholar
  29. 29.
    Weiss R, Dufour S, Taksali SE, et al.: Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003, 362:951–957.PubMedCrossRefGoogle Scholar
  30. 30.
    Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609–611.PubMedCrossRefGoogle Scholar
  31. 31.
    Garrison RJ, Kannel WB, Stokes J, Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:234–251.CrossRefGoogle Scholar
  32. 32.
    McFarlane SI, Winer N, Sowers JR: Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med 2003, 163:2696–2704.PubMedCrossRefGoogle Scholar
  33. 33.
    Sarzani R, Dessi-Fulgheri P, Salvi F, et al.: A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999, 17:1301–1305.PubMedCrossRefGoogle Scholar
  34. 34.
    McFarlane SI, Sowers JR: Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003, 88:516–523.PubMedCrossRefGoogle Scholar
  35. 35.
    Nannipieri M, Seghieri G, Catalano C, et al.: Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res 2002, 34:265–270.PubMedCrossRefGoogle Scholar
  36. 36.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.PubMedCrossRefGoogle Scholar
  37. 37.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  38. 38.
    Dekker JM, Girman C, Rhodes T, et al.: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112:666–673.PubMedCrossRefGoogle Scholar
  39. 39.
    Olshansky SJ, Passaro DJ, Hershow RC, et al.: A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138–1145.PubMedCrossRefGoogle Scholar
  40. 40.
    Whaley-Connell A, Palmer J, Sowers JR: Risk stratification and treatment options for hypertensive patients with metabolic syndrome and prediabetes. Johns Hopkins Advanced Studies in Medicine 2005, 5:S1011–S1018.Google Scholar
  41. 41.
    Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Obarzanek E, Sacks FM, Vollmer WM, et al.: Effects on blood lipids of a blood pressure lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001, 74:80–89.PubMedGoogle Scholar
  43. 43.
    American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(suppl 1):S71–S73.Google Scholar
  44. 44.
    Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661.PubMedGoogle Scholar
  45. 45.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.PubMedCrossRefGoogle Scholar
  46. 46.
    Hebert PR, Moser M, Mayer J, et al.: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578–581.PubMedCrossRefGoogle Scholar
  47. 47.
    Moser M. Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214–1218.PubMedCrossRefGoogle Scholar
  48. 48.
    Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997, 277:739–745.PubMedCrossRefGoogle Scholar
  49. 49.
    Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757–764.PubMedCrossRefGoogle Scholar
  50. 50.
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255–3264.Google Scholar
  51. 51.
    Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.PubMedCrossRefGoogle Scholar
  52. 52.
    Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.PubMedCrossRefGoogle Scholar
  53. 53.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:2981–2997.CrossRefGoogle Scholar
  54. 54.
    Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:713–720.Google Scholar
  55. 55.
    Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002, 359:1004–1010.PubMedCrossRefGoogle Scholar
  56. 56.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  57. 57.
    Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.PubMedCrossRefGoogle Scholar
  58. 58.
    Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.PubMedCrossRefGoogle Scholar
  59. 59.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259.Google Scholar
  60. 60.
    Khan K, Govindarajan G, Whaley-Connell A, Sowers JR: Diabetic hypertension. Heart Failure Clinics 2006, 2:25–36.PubMedCrossRefGoogle Scholar
  61. 61.
    Sowers JR, Reed J: 1999 Clinical advisory treatment of hypertension in diabetes. J Clin Hypertens (Greenwich) 2000, 2:132–133.Google Scholar
  62. 62.
    Larochelle P, Clack JM, Marbury TC, et al.: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997, 80:1613–1615.PubMedCrossRefGoogle Scholar
  63. 63.
    Whaley-Connell A, Sowers JR: Hypertension management in type 2 diabetes and the JNC VII. In Endocrinology and Metabolism Clinics of North Amercia. Edited by Einhorn D, Rosenstock J. Philadelphia: WB Saunders Company; 2005:63–75.Google Scholar
  64. 64.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.PubMedCrossRefGoogle Scholar
  65. 65.
    American Diabetes Association: Nephropathy in diabetes: clinical practice recommendations. Diabetes Care 2004, 27(suppl 1):S79–S83.Google Scholar
  66. 66.
    Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.PubMedCrossRefGoogle Scholar
  67. 67.
    Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.PubMedCrossRefGoogle Scholar
  68. 68.
    Gerstein HC, Yusuf S, Holman R, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519–1527.PubMedCrossRefGoogle Scholar
  69. 69.
    Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583–592.PubMedCrossRefGoogle Scholar
  70. 70.
    Pyorala K, Ballantyne CM, Gumbiner B, et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004, 27:1735–1740.PubMedCrossRefGoogle Scholar
  71. 71.
    Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998, 98:2513–2519.PubMedGoogle Scholar
  72. 72.
    Armitage J, Collins R: Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials MRC/BHF Heart Protection Study. Heart 2000, 84:357–360.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Sudha Ganne
  • Surender K. Arora
  • Olena Dotsenko
  • Samy I. McFarlane
  • Adam Whaley-Connell
    • 1
  1. 1.Internal Medicine, Division of NephrologyUniversity of Missouri-Columbia School of MedicineColumbiaUSA

Personalised recommendations